A Phase 1 interventional study of Quizartinib and Milademetan in Acute Myeloid Leukemia, sponsored by Daiichi Sankyo. Terminated at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-05-20.
Sponsored by Daiichi Sankyo · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing quizartinib in Leukemia, Myeloid, Acute — 6 open to participants now, 10 under way, 2 of them phase 3. quizartinib · Leukemia, Myeloid, Acute.
Among the 28 studies testing quizartinib in Leukemia, Myeloid, Acute, this one is the 24th largest by enrollment, is one of 4 that started in 2018, is one of 8 in phase 1, and was the 13th registered.
3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →6 of the 28 studies testing quizartinib in Leukemia, Myeloid, Acute are open now, in 9 countries. Recruiting first, the newest first:
PETHEMA Foundation · Sites in Spain
Ages 18+
Daiichi Sankyo · Sites in United States, Australia, Brazil and 2 more countries
Ages 18+
National Cancer Institute (NCI) · Sites in United States, Canada, Puerto Rico
Ages 18+
Princess Maxima Center for Pediatric Oncology · Sites in Netherlands
Ages 1 mo–18 yrs
Kura Oncology, Inc. · Sites in United States
Ages 18+
By country, each count listing its studies:
quizartinib: first FDA approval 2023 (VANFLYTA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 15 · Phase 3 5
First in 2007; this study’s year is marked. 4 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 10 is below the median of 40 across 3,007 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 69 across the 28 interventional studies. Of the 15 that completed or were terminated, 9 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 28 have an industry lead sponsor. The 10 most frequent:
Daiichi Sankyo is the lead sponsor of 322 studies on the registry; 37 are open to participants now.
Of its 51 completed or terminated interventional studies of FDA-regulated products, 38 (75%) have results posted.
21 studies in Leukemia, Myeloid, Acute by Daiichi Sankyo: 1 open now, 3 under way, 1 of them phase 3. Of 18 finished, 12 (67%) have results posted.
Among the 21 studies in Leukemia, Myeloid, Acute by Daiichi Sankyo, this one is the 18th largest by enrollment of the 20 interventional ones that give a count, is one of 4 that started in 2018, is one of 12 in phase 1, and was the 16th registered.
Daiichi Sankyo’s Leukemia, Myeloid, Acute studies by the year they started, since 1999.
1 of the studies testing quizartinib in Leukemia, Myeloid, Acute that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03793478Daiichi SankyoSafety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood | 2027-05-01 |
Add it to your calendar (.ics) → With an account.
Among the 28 studies testing quizartinib in Leukemia, Myeloid, Acute, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Daiichi Sankyo’s 21 in Leukemia, Myeloid, Acute:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Participants with AML that have gone into remission and come back (relapsed) or gone into remission with a number of leukemia cells still in their system (refractory) will be recruited for this study. They will also be positive for FLT3-ITD mutation.
Participants will receive a combined dose of quizartinib and milademetan that have not been approved by the US Food and Drug Administration yet (m).
The combination of these drugs will be provided in different amounts on defined days (dosing schedules).
It is expected that the combination of milademetan and quizartinib will be safe and well tolerated. It is expected that the combination may fight the leukemia better than a single drug.
The study will run for approximately 3 years. There may be up to 156 participants.
The study has 2 parts:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Has any history or medical condition, condition, drug/medication use or other condition that might, per protocol or in the opinion of the investigator, compromise:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with relapsed/refractory FLT3-ITD Mutant AML receive quizartinib + milademetan at increasing and/or decreasing doses and schedules
Drug: Quizartinib · Drug: Milademetan
Participants with relapsed/refractory FLT3-ITD Mutant AML receive the recommended dose of quizartinib + milademetan determined by Part 1
Drug: Quizartinib · Drug: Milademetan
Participants with newly diagnosed FLT3-ITD Mutant AML unfit for chemotherapy receive the recommended dose of quizartinib + milademetan determined by Part 1
Drug: Quizartinib · Drug: Milademetan
20 or 30 mg tablets for oral administration
Also known as: AC220, Vanflyta
5, 20, 80 or 200 mg capsules for oral administration
Also known as: DS-3032b
5, 20, 80 or 200 mg capsules for oral administration; 30, 45, 80, or 100 mg capsules may be utilized
Also known as: DS-3032b
Number of Participants With Dose Limiting Toxicities (DLTs) Following Administration of Milademetan in Combination With Quizartinib
A dose limiting toxicity (DLT) is defined as any non-hematological treatment-emergent adverse event (TEAE) unless incontrovertibly related to disease progression, intercurrent illness, or concomitant medication, that occurs during the DLT evaluation period (28 days) in each dose level cohort, and is Grade 3 or higher according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0, with exceptions specified: Grade 3 or higher aspartate aminotransferase (AST)/alanine aminotransferase (ALT) levels, OR elevation in total bilirubin ≥3.0 × upper limit of normal (ULN) that does not return to ≤Grade 2 elevation within 7 days. Absolute neutrophil count (ANC) \<0.5 × 10\^9/L, platelets \<20 × 10\^9/L, and marrow cellularity \<5% at 6 weeks or later from start of therapy without any evidence of leukemia.
Time frame: Baseline up to 28 days (Cycle 1) from the start of study drug administration
Number of Participants With Any Treatment-emergent Adverse Events by System Organ Class Following Administration of Milademetan in Combination With Quizartinib
A treatment-emergent adverse event (TEAE) is defined as an adverse event (AE) that emerges during the treatment period (from date of first dose up to 35 days after the last dose of the study treatment), having been absent at pretreatment; or reemerges during treatment, having been present at baseline but stopped prior to treatment; or worsens in severity after starting treatment related to the pretreatment state, when the AE is continuous. AEs collected after 35 days after the last dose of study drug were not considered TEAEs unless they were treatment-related.
Time frame: Baseline up to 35 days after last dose of study drug, up to approximately 2 years 3 months
Number of Participants With Best Overall Response Following Administration of Milademetan in Combination With Quizartinib
Based on European LeukemiaNet criteria, complete remission (CR) was bone marrow (BM) blasts \<5%, absence of circulating blasts/blasts with Auer rods, absence of extramedullary disease (EMD), absolute neutrophil count (ANC) ≥1.0×10\^9/L, and platelet count ≥100×10\^9/L; CR with Incomplete Blood Count Recovery (CRi): all CR criteria except for residual neutropenia or thrombocytopenia; Morphologic Leukemia Free State (MLFS): BM blasts \<5%, absence of blasts with Auer rods, absence of EMD, and no hematologic recovery required; Partial Remission (PR): decrease of BM blast percentage by at least 50% (to 5% to 25%) and all criteria of CR; Stable disease: absence of CR, CRi, MLFS, or PR, and criteria for progressive disease (PD) not met; Relapse (after CR/CRi): BM blasts ≥5%, or reappearance of leukemic blasts, or EMD development; and PD: increase in BM blast % and/or increase of absolute blast counts: \>50% increase in marrow blasts over baseline, \>50% increase in peripheral blasts, or new EMD.
Time frame: Baseline up to first documented response, disease progression, withdrawal, or death (whichever occurs first), up to approximately 2 years 3 months
Overall Response Rate Following Administration of Milademetan in Combination With Quizartinib
Overall response rate was defined as the number of participants with composite Complete Remission (CRc)+Morphological Leukemia Free State (MLFS)+Partial Remission (PR) based on the European LeukemiaNet criteria. Based on the European LeukemiaNet criteria, CRc was defined as complete remission (CR) as bone marrow (BM) blasts \<5%, absence of circulating blasts/blasts with Auer rods, absence of extramedullary disease (EMD), absolute neutrophil count (ANC) ≥1.0×10\^9/L, and platelet count ≥100×10\^9/L; CR with Incomplete Blood Count Recovery (CRi): all CR criteria except for residual neutropenia or thrombocytopenia; Morphologic Leukemia Free State (MLFS): BM blasts \<5%, absence of blasts with Auer rods, absence of EMD, and no hematologic recovery required; Partial Remission (PR): decrease of BM blast percentage by at least 50% (to 5% to 25%) and all criteria of CR.
Time frame: Baseline up to first documented response, disease progression, withdrawal, or death (whichever occurs first), up to approximately 2 years 3 months
A total of 10 out of the 22 screened participants who met all inclusion criteria and no exclusion criteria were enrolled in the study at 8 clinic sites in the United States. Only Part 1 is reported since the study terminated prior to Part 2.
| Milestone | Part 1, Cohort 1: Quizartinib + Milademetan | Part 1, Cohort 1A: Quizartinib + Milademetan |
|---|---|---|
| Started | 4 | 6 |
| Completed | 0 | 0 |
| Not completed | 4 | 6 |
| Withdrew: Death | 3 | 0 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Lack of efficacy | 0 | 2 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Study terminated by sponsor | 0 | 1 |
| Withdrew: Other | 0 | 2 |
A dose limiting toxicity (DLT) is defined as any non-hematological treatment-emergent adverse event (TEAE) unless incontrovertibly related to disease progression, intercurrent illness, or concomitant medication, that occurs during the DLT evaluation period (28 days) in each dose level cohort, and is Grade 3 or higher according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0, with exceptions specified: Grade 3 or higher aspartate aminotransferase (AST)/alanine aminotransferase (ALT) levels, OR elevation in total bilirubin ≥3.0 × upper limit of normal (ULN) that does not return to ≤Grade 2 elevation within 7 days. Absolute neutrophil count (ANC) \<0.5 × 10\^9/L, platelets \<20 × 10\^9/L, and marrow cellularity \<5% at 6 weeks or later from start of therapy without any evidence of leukemia.
| Participants | Part 1, Cohort 1: Quizartinib + Milademetan | Part 1, Cohort 1A: Quizartinib + Milademetan |
|---|---|---|
| Number of Participants With Dose Limiting Toxicities (DLTs) Following Administration of Milademetan in Combination With Quizartinib | 1 | 0 |
A treatment-emergent adverse event (TEAE) is defined as an adverse event (AE) that emerges during the treatment period (from date of first dose up to 35 days after the last dose of the study treatment), having been absent at pretreatment; or reemerges during treatment, having been present at baseline but stopped prior to treatment; or worsens in severity after starting treatment related to the pretreatment state, when the AE is continuous. AEs collected after 35 days after the last dose of study drug were not considered TEAEs unless they were treatment-related.
| Participants | Part 1, Cohort 1: Quizartinib + Milademetan | Part 1, Cohort 1A: Quizartinib + Milademetan |
|---|---|---|
| Any TEAEs | 4 | 6 |
| Any Blood and Lymphatic System Disorders | 2 | 5 |
| Any Cardiac Disorders | 1 | 2 |
| Any Ear and Labyrinth Disorders | 1 | 1 |
| Any Eye Disorders | 2 | 0 |
| Any Gastrointestinal Disorders | 4 | 6 |
| Any General Disorders and Administration Site Conditions | 3 | 5 |
| Any Immune System Disorders | 1 | 0 |
| Any Infections and Infestations | 4 | 1 |
| Any Injury, Poisoning and Procedural Complications | 0 | 3 |
| Any Investigations | 3 | 5 |
| Any Metabolism and Nutrition Disorders | 4 | 5 |
| Any Musculoskeletal and Connective Tissue Disorders | 2 | 4 |
| Any Nervous System Disorders | 4 | 3 |
| Any Psychiatric Disorders | 2 | 2 |
| Any Renal and Urinary Disorders | 1 | 2 |
| Any Respiratory, Thoracic, and Mediastinal Disorders | 4 | 4 |
| Any Skin and Subcutaneous Tissue Disorders | 3 | 5 |
| Any Vascular Disorders | 3 | 1 |
Based on European LeukemiaNet criteria, complete remission (CR) was bone marrow (BM) blasts \<5%, absence of circulating blasts/blasts with Auer rods, absence of extramedullary disease (EMD), absolute neutrophil count (ANC) ≥1.0×10\^9/L, and platelet count ≥100×10\^9/L; CR with Incomplete Blood Count Recovery (CRi): all CR criteria except for residual neutropenia or thrombocytopenia; Morphologic Leukemia Free State (MLFS): BM blasts \<5%, absence of blasts with Auer rods, absence of EMD, and no hematologic recovery required; Partial Remission (PR): decrease of BM blast percentage by at least 50% (to 5% to 25%) and all criteria of CR; Stable disease: absence of CR, CRi, MLFS, or PR, and criteria for progressive disease (PD) not met; Relapse (after CR/CRi): BM blasts ≥5%, or reappearance of leukemic blasts, or EMD development; and PD: increase in BM blast % and/or increase of absolute blast counts: \>50% increase in marrow blasts over baseline, \>50% increase in peripheral blasts, or new EMD.
| Participants | Part 1, Cohort 1: Quizartinib + Milademetan | Part 1, Cohort 1A: Quizartinib + Milademetan |
|---|---|---|
| Complete remission (CR) | 0 | 0 |
| Complete Remission with Partial Hematological Recovery (CRh) | 0 | 0 |
| Complete Remission with Incomplete Blood Count Recovery (CRi) | 1 | 3 |
| Morphologic Leukemia Free State (MLFS) | 0 | 0 |
| Partial Remission (PR) | 0 | 0 |
| Stable Disease (SD) | 1 | 2 |
| Relapse | 0 | 0 |
| Missing | 2 | 1 |
Overall response rate was defined as the number of participants with composite Complete Remission (CRc)+Morphological Leukemia Free State (MLFS)+Partial Remission (PR) based on the European LeukemiaNet criteria. Based on the European LeukemiaNet criteria, CRc was defined as complete remission (CR) as bone marrow (BM) blasts \<5%, absence of circulating blasts/blasts with Auer rods, absence of extramedullary disease (EMD), absolute neutrophil count (ANC) ≥1.0×10\^9/L, and platelet count ≥100×10\^9/L; CR with Incomplete Blood Count Recovery (CRi): all CR criteria except for residual neutropenia or thrombocytopenia; Morphologic Leukemia Free State (MLFS): BM blasts \<5%, absence of blasts with Auer rods, absence of EMD, and no hematologic recovery required; Partial Remission (PR): decrease of BM blast percentage by at least 50% (to 5% to 25%) and all criteria of CR.
| Participants | Part 1, Cohort 1: Quizartinib + Milademetan | Part 1, Cohort 1A: Quizartinib + Milademetan |
|---|---|---|
| Overall Response Rate Following Administration of Milademetan in Combination With Quizartinib | 1 | 3 |
Collected over Treatment-emergent adverse events (TEAEs) were collected from date of first dose up to 35 days after last dose of study drug, up to approximately 2 years 3 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1, Cohort 1: Quizartinib + Milademetan | 3/4 (75%) | 4/4 (100%) | 4/4 (100%) |
| Part 1, Cohort 1A: Quizartinib + Milademetan | 1/6 (16.7%) | 3/6 (50%) | 6/6 (100%) |
| Event | Part 1, Cohort 1: Quizartinib + Milademetan | Part 1, Cohort 1A: Quizartinib + Milademetan |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 1/4 | 0/6 |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/4 | 0/6 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/4 | 0/6 |
| BradycardiaCardiac disorders | 1/4 | 0/6 |
| Arthritis infectiveInfections and infestations | 1/4 | 0/6 |
| SepsisInfections and infestations | 1/4 | 0/6 |
| Septic shockInfections and infestations | 1/4 | 0/6 |
| Sinusitis fungalInfections and infestations | 1/4 | 0/6 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 1/4 | 1/6 |
| HaematomaVascular disorders | 1/4 | 0/6 |
| Event | Part 1, Cohort 1: Quizartinib + Milademetan | Part 1, Cohort 1A: Quizartinib + Milademetan |
|---|---|---|
| HypomagnesaemiaMetabolism and nutrition disorders | 3/4 | 2/6 |
| CoughRespiratory, thoracic and mediastinal disorders | 3/4 | 2/6 |
| DiarrhoeaGastrointestinal disorders | 2/4 | 4/6 |
| NauseaGastrointestinal disorders | 2/4 | 4/6 |
| FatigueGeneral disorders | 1/4 | 4/6 |
| Decreased appetiteMetabolism and nutrition disorders | 2/4 | 4/6 |
| HypokalaemiaMetabolism and nutrition disorders | 2/4 | 4/6 |
| AnaemiaBlood and lymphatic system disorders | 1/4 | 3/6 |
| Febrile neutropeniaBlood and lymphatic system disorders | 2/4 | 1/6 |
| VomitingGastrointestinal disorders | 2/4 | 3/6 |
Demographics and baseline characteristics were assessed in the Enrolled Analysis Set.
| Age, Continuous(years) | Part 1, Cohort 1: Quizartinib + Milademetan | Part 1, Cohort 1A: Quizartinib + Milademetan | Total |
|---|---|---|---|
| Median | 64 (51 to 72) | 65 (51 to 81) | 64 (51 to 81) |
| Sex: Female, Male(Participants) | Part 1, Cohort 1: Quizartinib + Milademetan | Part 1, Cohort 1A: Quizartinib + Milademetan | Total |
|---|---|---|---|
| Female | 0 | 2 | 2 |
| Male | 4 | 4 | 8 |
| Race (NIH/OMB)(Participants) | Part 1, Cohort 1: Quizartinib + Milademetan | Part 1, Cohort 1A: Quizartinib + Milademetan | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 4 | 5 | 9 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Region of Enrollment(participants) | Part 1, Cohort 1: Quizartinib + Milademetan | Part 1, Cohort 1A: Quizartinib + Milademetan | Total |
|---|---|---|---|
| United States | 4 | 6 | 10 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.
Access criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.
Data sharing details ↗ · vivli.org
Ran from Dec 2018 to primary completion in Apr 2021, 27 months.
Results were first posted in May 2022, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Quizartinib · Milademetan